Editors’ Picks, October 2026: Surgical De-escalation, New CAR T-cell Approaches, and More
The October 2026 Editors’ Picks from AACR journals include findings on multiple primary cancers in World Trade Center responders,...
Tag: Pancreatic cancer
The October 2026 Editors’ Picks from AACR journals include findings on multiple primary cancers in World Trade Center responders,...
At the recent AACR Conference on Pancreatic Cancer, researchers explored the complex interactions among tumor cells, neurons, and the...
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and...
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.